HEURON Global Signs MOU with Thammasat University Hospital to Validate AI Stroke Solution

Feb. 2026

Launches Southeast Asia Commercialization Model with Path Toward Paid Deployment



HEURON Global Co., Ltd. announced that it has signed a Memorandum of Understanding (MOU) with Thammasat University Hospital, one of Thailand’s leading national university hospitals, to conduct clinical validation of its artificial intelligence (AI)-based stroke analysis solution with the goal of transitioning to paid use.

HEURON Global is a Thailand-based joint venture subsidiary of Korean neuroimaging AI company HEURON Co., Ltd. The agreement focuses on deploying and evaluating the company’s AI-powered stroke analysis technology in a real-world clinical environment to establish the clinical and operational evidence necessary for future commercial conversion.

The signing ceremony was attended by Prof. Dr. Dirok Piyayotai, Director of Thammasat University Hospital, and Tula Rikkrasaritkun, Director of HEURON Global, where both parties shared their strategic direction and phased implementation plan.


Here is the finalized English news article version, structured in a professional international press style:


HEURON Global Signs MOU with Thammasat University Hospital to Validate AI Stroke Solution

Launches Southeast Asia Commercialization Model with Path Toward Paid Deployment

HEURON Global Co., Ltd. announced that it has signed a Memorandum of Understanding (MOU) with Thammasat University Hospital, one of Thailand’s leading national university hospitals, to conduct clinical validation of its artificial intelligence (AI)-based stroke analysis solution with the goal of transitioning to paid use.

HEURON Global is a Thailand-based joint venture subsidiary of Korean neuroimaging AI company HEURON Co., Ltd. The agreement focuses on deploying and evaluating the company’s AI-powered stroke analysis technology in a real-world clinical environment to establish the clinical and operational evidence necessary for future commercial conversion.

The signing ceremony was attended by Prof. Dr. Dirok Piyayotai, Director of Thammasat University Hospital, and Tula Rikkrasaritkun, Director of HEURON Global, where both parties shared their strategic direction and phased implementation plan.


Comprehensive Evaluation in Acute Stroke Workflow

Under the collaboration, the two organizations will conduct a multi-dimensional evaluation covering:

  • Diagnostic accuracy of the AI system

  • Clinical decision-support value

  • Integration feasibility within existing clinical workflows

  • Operational efficiency improvements

Acute stroke care is a time-critical domain where rapid diagnosis and treatment decisions directly influence patient outcomes. The partners plan to closely assess how AI-driven imaging analysis can support emergency triage and therapeutic decision-making in real clinical practice.

Thammasat University Hospital is recognized as a major tertiary referral center in central Thailand. Its cerebrovascular center operates an integrated care pathway encompassing emergency triage, imaging diagnosis, interventional procedures, intensive care, and rehabilitation coordination for acute stroke patients. Supported by a multidisciplinary collaboration among neurology, radiology, and emergency medicine departments, the hospital maintains standardized and high-speed treatment protocols. As a university hospital, it also actively contributes to clinical research and protocol development.

HEURON Global stated that, given the hospital’s clinical stature and operational capacity, its cerebrovascular center represents a high-value reference site for validating paid adoption and broader market expansion within Thailand.


HEURON Global Positioned as Southeast Asia Expansion Hub

Established on January 12, 2026, HEURON Global was formed as a joint venture to strengthen HEURON’s business development across Thailand and the broader Asian region. Headquartered in Bangkok, the company oversees regional operations and service deployment in Singapore, Vietnam, Indonesia, Malaysia, and India.

Through its collaboration with Thammasat University Hospital, HEURON Global plans to systematically accumulate clinical reference data and operational standards in Thailand. Based on these validated results, the company intends to expand partnerships with additional hospitals and advance its broader Southeast Asia market strategy.

A HEURON Global representative commented,

“This agreement represents not merely a technology introduction, but a structured clinical validation phase aimed at paid commercial transition. By building an operational model optimized for the local healthcare environment, we aim to establish a sustainable business foundation across Thailand and Southeast Asia.”

TOP